Analyst Price Target is $33.80
▲ +87.47% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for NewAmsterdam Pharma in the last 3 months. The average price target is $33.80, with a high forecast of $37.00 and a low forecast of $30.00. The average price target represents a 87.47% upside from the last price of $18.03.
Current Consensus is
Buy
The current consensus among 7 polled investment analysts is to buy stock in NewAmsterdam Pharma. This Buy consensus rating has held steady for over two years.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Read More